{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:04:20Z","timestamp":1793124260626,"version":"4.5.0"},"reference-count":115,"publisher":"Walter de Gruyter GmbH","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Concerns regarding contrast-induced acute kidney injury (CI-AKI) remain significant due to the increasing use of iodinated contrast agents (ICM) in diagnostic and medical procedures. Although the frequency of CI-AKI has decreased over the decades, it continues to be a major cause of hospital-acquired acute kidney damage, thereby elevating the risk of mortality, morbidity, and prolonged hospital stays. The complex pathophysiology of CI-AKI involves vasoconstriction, oxidative stress, renal medullary hypoxia, inflammatory responses, and direct tubular toxicity. Recent discoveries have identified ferroptosis and neutrophil extracellular traps (NETs) as additional mechanisms contributing to endothelial and tubular damage. Furthermore, microRNAs such as miR-30c, miR-21, and miR-141-3p have emerged as preliminary biomarkers and therapeutic targets due to their regulatory effects on cellular apoptosis and inflammatory pathways. Procedural controversies persist regarding the risk differences between intravenous and intra-arterial contrast administration; however, evidence suggests that patient comorbidities and procedural complexity, rather than the route of administration alone, determine the risk of CI-AKI. Risk stratification tools, such as the Mehran and ACEF scores, provide frameworks for identifying high-risk patients and guiding preventive strategies. This review integrates an understanding of the molecular pathogenesis of CI-AKI, clarifies procedural debates, and highlights emerging biomarkers and risk models.<\/jats:p>","DOI":"10.1515\/jbcpp-2025-0222","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T18:27:33Z","timestamp":1770056853000},"page":"201-212","source":"Crossref","is-referenced-by-count":3,"title":["Contrast-induced acute kidney injury: from pathophysiology to risk prediction and prevention strategies"],"prefix":"10.1515","volume":"37","author":[{"given":"Pooja","family":"Anjanappa","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice , Sri Adichunchanagiri College of Pharmacy, Adichunchanagiri University , BG Nagara , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita","family":"Kularia","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Faculty of Pharmacy , Parul University , Vadodara , Gujarat , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3032-5802","authenticated-orcid":false,"given":"Yogendra","family":"Shrestha","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Faculty of Pharmacy , Parul University , Vadodara , Gujarat , India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_001","doi-asserted-by":"crossref","unstructured":"Vlachopanos, G, Schizas, D, Hasemaki, N, Georgalis, A. Pathophysiology of contrast-induced acute kidney injury (CIAKI). Curr Pharm Des 2019;25:4642\u20137. https:\/\/doi.org\/10.2174\/1381612825666191210152944.","DOI":"10.2174\/1381612825666191210152944"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_002","doi-asserted-by":"crossref","unstructured":"Chaudhari, H, Mahendrakar, S, Baskin, SE, Reddi, AS. Contrast-induced acute kidney injury: evidence in support of its existence and a review of its pathogenesis and management. Int J Nephrol Renovascular Dis 2022:253\u201366. https:\/\/doi.org\/10.2147\/ijnrd.s371700.","DOI":"10.2147\/IJNRD.S371700"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_003","doi-asserted-by":"crossref","unstructured":"Wang, Y, Liu, K, Xie, X, Song, B. Contrast-associated acute kidney injury: an update of risk factors, risk factor scores, and preventive measures. Clin Imag 2021;69:354\u201362. https:\/\/doi.org\/10.1016\/j.clinimag.2020.10.009.","DOI":"10.1016\/j.clinimag.2020.10.009"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_004","doi-asserted-by":"crossref","unstructured":"Alhozali, HM, Qutub, M, Alharbi, NM, Awlia, GW, Alraddadi, MI, Algarni, AA, et al.. The risk of acute kidney injury in patients undergoing coronary angiography. J\u00a0Contemp Med Sci 2024;10:185. https:\/\/doi.org\/10.22317\/jcms.v10i3.1509.","DOI":"10.22317\/jcms.v10i3.1509"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_005","doi-asserted-by":"crossref","unstructured":"Lei, L, Xue, Y, Guo, Z, Liu, B, He, Y, Song, F, et al.. Population attributable risk estimates of risk factors for contrast-induced acute kidney injury following coronary angiography: a cohort study. BMC Cardiovasc Disord 2020;20:289. https:\/\/doi.org\/10.1186\/s12872-020-01570-6.","DOI":"10.1186\/s12872-020-01570-6"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_006","doi-asserted-by":"crossref","unstructured":"Deng, K, Pei, M, Li, B, Yang, N, Wang, Z, Wan, X, et al.. Signal pathways involved in contrast- induced acute kidney injury. Front Physiol 2024;15:1490725. https:\/\/doi.org\/10.3389\/fphys.2024.1490725.","DOI":"10.3389\/fphys.2024.1490725"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_007","doi-asserted-by":"crossref","unstructured":"Zhu, Z, Li, J, Song, Z, Li, T, Li, Z, Gong, X. Tetramethylpyrazine attenuates renal tubular epithelial cell ferroptosis in contrast-induced nephropathy by inhibiting transferrin receptor and intracellular reactive oxygen species. Clin Sci 2024;138:235\u201349. https:\/\/doi.org\/10.1042\/cs20231184.","DOI":"10.1042\/CS20231184"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_008","doi-asserted-by":"crossref","unstructured":"Wang, H, Gao, T, Zhang, R, Hu, J, Gao, S, Wang, Y, et al.. Neutrophil extracellular traps aggravate contrast-induced acute kidney injury by damaging glomeruli and peritubular capillaries. J\u00a0Inflamm Res 2023;16:5629\u201346. https:\/\/doi.org\/10.2147\/jir.s433110.","DOI":"10.2147\/JIR.S433110"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_009","doi-asserted-by":"crossref","unstructured":"Wang, B, Xu, J, Fu, P, Ma, L. MicroRNAs in septic acute kidney injury. Burns Trauma 2023;11:tkad008. https:\/\/doi.org\/10.1093\/burnst\/tkad008.","DOI":"10.1093\/burnst\/tkad008"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_010","doi-asserted-by":"crossref","unstructured":"S\u016fva, M, Kala, P, Poloczek, M, Ka\u0148ovsk\u00fd, J, \u0160t\u00edpal, R, Radvan, M, et al.. Contrast-induced acute kidney injury and its contemporary prevention. Front Cardiovasc Med 2022;9:1073072. https:\/\/doi.org\/10.3389\/fcvm.2022.1073072.","DOI":"10.3389\/fcvm.2022.1073072"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_011","doi-asserted-by":"crossref","unstructured":"Kooiman, J, Le Haen, PA, Gezgin, G, de Vries, JP, Boersma, D, Brulez, HF, et al.. Contrast-induced acute kidney injury and clinical outcomes after intra-arterial and intravenous contrast administration: risk comparison adjusted for patient characteristics by design. Am Heart J 2013;165:793\u20139. https:\/\/doi.org\/10.1016\/j.ahj.2013.02.013.","DOI":"10.1016\/j.ahj.2013.02.013"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_012","doi-asserted-by":"crossref","unstructured":"Brillantino, D, Bignardi, E, Tufano, A, Zeccolini, R, Zeccolini, M. Clinical pharmacology, use, and adverse reactions of intravenous iodinated contrast media in computed tomography. J\u00a0Radiol Imaging 2020;4:1\u20137.","DOI":"10.14312\/2399-8172.2020-1"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_013","unstructured":"Rogers, DC, Tadi, P, StatPearls [Internet]. In: Intravenous Contrast. Treasure Island (FL): StatPearls Publishing; 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557794\/[Accessed 13 Mar 2023]."},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_014","doi-asserted-by":"crossref","unstructured":"Harbron, R, Ainsbury, EA, Bouffler, SD, Tanner, RJ, Eakins, JS, Pearce, MS. Enhanced radiation dose and DNA damage associated with iodinated contrast media in diagnostic X-ray imaging. Br J Radiol 2017;90:20170028. https:\/\/doi.org\/10.1259\/bjr.20170028.","DOI":"10.1259\/bjr.20170028"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_015","doi-asserted-by":"crossref","unstructured":"Li, Y, Wang, J. Contrast-induced acute kidney injury: a review of definition, pathogenesis, risk factors, prevention and treatment. BMC Nephrol 2024;25:140. https:\/\/doi.org\/10.1186\/s12882-024-03570-6.","DOI":"10.1186\/s12882-024-03570-6"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_016","doi-asserted-by":"crossref","unstructured":"Andreucci, M, Faga, T, Pisani, A, Sabbatini, M, Michael, A. Pathogenesis of acute renal failure induced by iodinated radiographic contrast media. Austin J Nephrol Hypertens 2014;1:1005.","DOI":"10.1155\/2014\/691623"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_017","doi-asserted-by":"crossref","unstructured":"Silva, BR, Paula, TD, Paulo, M, Bendhack, LM. Nitric oxide signaling and the cross talk with prostanoids pathways in vascular system. Med Chem 2017;13:319\u201333. https:\/\/doi.org\/10.2174\/1573406412666161228115627.","DOI":"10.2174\/1573406412666161228115627"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_018","doi-asserted-by":"crossref","unstructured":"Heyman, SN, Rosen, S, Khamaisi, M, Id\u00e9e, JM, Rosenberger, C. Reactive oxygen species and the pathogenesis of radiocontrast-induced nephropathy. Investig Radiol 2010;45:188\u201395. https:\/\/doi.org\/10.1097\/rli.0b013e3181d2eed8.","DOI":"10.1097\/RLI.0b013e3181d2eed8"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_019","doi-asserted-by":"crossref","unstructured":"Pisani, A, Riccio, E, Andreucci, M, Faga, T, Ashour, M, Di Nuzzi, A, et al.. Role of reactive oxygen species in pathogenesis of radiocontrast\u2010induced nephropathy. BioMed Res Int 2013;2013:868321. https:\/\/doi.org\/10.1155\/2013\/868321.","DOI":"10.1155\/2013\/868321"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_020","doi-asserted-by":"crossref","unstructured":"Caiazza, A, Russo, L, Sabbatini, M, Russo, D. Hemodynamic and tubular changes induced by contrast media. BioMed Res Int 2014;2014:578974. https:\/\/doi.org\/10.1155\/2014\/578974.","DOI":"10.1155\/2014\/578974"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_021","doi-asserted-by":"crossref","unstructured":"Romano, G, Briguori, C, Quintavalle, C, Zanca, C, Rivera, NV, Colombo, A, et al.. Contrast agents and renal cell apoptosis. Eur Heart J 2008;29:2569\u201376. https:\/\/doi.org\/10.1093\/eurheartj\/ehn197.","DOI":"10.1093\/eurheartj\/ehn197"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_022","doi-asserted-by":"crossref","unstructured":"Cashion, W, Weisbord, SD. Radiographic contrast media and the kidney. Clin J Am Soc Nephrol 2022;17:1234\u201342. https:\/\/doi.org\/10.2215\/cjn.16311221.","DOI":"10.2215\/CJN.16311221"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_023","doi-asserted-by":"crossref","unstructured":"Wang, Z, Wang, Q, Gong, X. Unveiling the mysteries of contrast-induced acute kidney injury: new horizons in pathogenesis and prevention. Toxics 2024;12:620. https:\/\/doi.org\/10.3390\/toxics12080620.","DOI":"10.3390\/toxics12080620"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_024","doi-asserted-by":"crossref","unstructured":"Fan, PC, Chen, CC, Chen, YC, Chang, YS, Chu, PH. MicroRNAs in acute kidney injury. Hum Genom 2016;10:29. https:\/\/doi.org\/10.1186\/s40246-016-0085-z.","DOI":"10.1186\/s40246-016-0085-z"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_025","doi-asserted-by":"crossref","unstructured":"Liu, Y, Liu, B, Liu, Y, Chen, S, Yang, J, Liu, J, et al.. MicroRNA expression profile by next-generation sequencing in a novel rat model of contrast-induced acute kidney injury. Ann Transl Med 2019;7:178. https:\/\/doi.org\/10.21037\/atm.2019.04.44.","DOI":"10.21037\/atm.2019.04.44"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_026","doi-asserted-by":"crossref","unstructured":"Wang, Z, Bao, W, Zou, X, Tan, P, Chen, H, Lai, C, et al.. Co-expression analysis reveals dysregulated miRNAs and miRNA-mRNA interactions in the development of contrast-induced acute kidney injury. PLoS One 2019;14:e0218574. https:\/\/doi.org\/10.1371\/journal.pone.0218574.","DOI":"10.1371\/journal.pone.0218574"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_027","doi-asserted-by":"crossref","unstructured":"Mihaljevi\u0107, J, Mihaljevi\u0107, D, Drenjan\u010devi\u0107, I, Sita\u0161, Z. The role of miRNAs in the regulation of oxidative stress and microvascular reactivity in chronic kidney disease. Proc Shevchenko Sci Soc Med Sci 2024;73:1\u201310. https:\/\/doi.org\/10.25040\/ntsh.","DOI":"10.25040\/ntsh2024.01.06"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_028","doi-asserted-by":"crossref","unstructured":"Magenta, A, Greco, S, Gaetano, C, Martelli, F. Oxidative stress and microRNAs in vascular diseases. Int J Mol Sci 2013;14:17319\u201346. https:\/\/doi.org\/10.3390\/ijms140917319.","DOI":"10.3390\/ijms140917319"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_029","doi-asserted-by":"crossref","unstructured":"Tsuji, K, Nakanoh, H, Fukushima, K, Kitamura, S, Wada, J. MicroRNAs as biomarkers and therapeutic targets for acute kidney injury. Diagnostics 2023;13:2893. https:\/\/doi.org\/10.3390\/diagnostics13182893.","DOI":"10.3390\/diagnostics13182893"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_030","doi-asserted-by":"crossref","unstructured":"Guan, XF, Chen, QJ, Zuo, XC, Guo, R, Peng, XD, Wang, JL, et al.. Contrast media- induced renal inflammation is mediated through HMGB1 and its receptors in human tubular cells. DNA Cell Biol 2017;36:67\u201376. https:\/\/doi.org\/10.1089\/dna.2016.3463.","DOI":"10.1089\/dna.2016.3463"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_031","doi-asserted-by":"crossref","unstructured":"Liu, J, Jia, Z, Gong, W. Circulating mitochondrial DNA stimulates innate immune signaling pathways to mediate acute kidney injury. Front Immunol 2021;12:680648. https:\/\/doi.org\/10.3389\/fimmu.2021.680648.","DOI":"10.3389\/fimmu.2021.680648"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_032","doi-asserted-by":"crossref","unstructured":"Hosohata, K, Harnsirikarn, T, Chokesuwattanaskul, S. Ferroptosis: a potential therapeutic target in acute kidney injury. Int J Mol Sci 2022;23:6583. https:\/\/doi.org\/10.3390\/ijms23126583.","DOI":"10.3390\/ijms23126583"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_033","unstructured":"Ponka, P, Beaumont, C, Richardson, DR. Function and regulation of transferrin and ferritin. InSeminars Hematol 1998;35:35\u201354."},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_034","doi-asserted-by":"crossref","unstructured":"Wang, J, Pantopoulos, K. Regulation of cellular iron metabolism. Biochem J 2011;434:365\u201381. https:\/\/doi.org\/10.1042\/bj20101825.","DOI":"10.1042\/BJ20101825"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_035","doi-asserted-by":"crossref","unstructured":"Zhu, Z, Li, J, Song, Z, Li, T, Li, Z, Gong, X. Tetramethylpyrazine attenuates renal tubular epithelial cell ferroptosis in contrast-induced nephropathy by inhibiting transferrin receptor and intracellular reactive oxygen species. Clin Sci 2024;138:235\u201349. https:\/\/doi.org\/10.1042\/cs20231184.","DOI":"10.1042\/CS20231184"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_036","doi-asserted-by":"crossref","unstructured":"Refaat, B, Abdelghany, AH, BaSalamah, MA, El-Boshy, M, Ahmad, J, Idris, S. Acute and chronic iron overloading differentially modulates the expression of cellular iron-homeostatic molecules in normal rat kidney. J\u00a0Histochem Cytochem 2018;66:825\u201339. https:\/\/doi.org\/10.1369\/0022155418782696.","DOI":"10.1369\/0022155418782696"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_037","doi-asserted-by":"crossref","unstructured":"Zarjou, A, Bolisetty, S, Joseph, R, Traylor, A, Apostolov, EO, Arosio, P, et al.. Proximal tubule H-ferritin mediates iron trafficking in acute kidney injury. J\u00a0Clin Investig 2013;123:4423\u201334. https:\/\/doi.org\/10.1172\/jci67867.","DOI":"10.1172\/JCI67867"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_038","doi-asserted-by":"crossref","unstructured":"Liu, J, Han, X, Zhou, J, Leng, Y. Molecular mechanisms of ferroptosis and their involvement in acute kidney injury. J\u00a0Inflamm Res 2023:4941\u201351. https:\/\/doi.org\/10.2147\/jir.s427505.","DOI":"10.2147\/JIR.S427505"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_039","doi-asserted-by":"crossref","unstructured":"Chen, Q, Guan, X, Zuo, X, Wang, J, Yin, W. The role of high mobility group box 1 (HMGB1) in the pathogenesis of kidney diseases. Acta Pharm Sin B 2016;6:183\u20138. https:\/\/doi.org\/10.1016\/j.apsb.2016.02.004.","DOI":"10.1016\/j.apsb.2016.02.004"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_040","doi-asserted-by":"crossref","unstructured":"Wang, X, Chen, J, Xu, J, Xie, J, Harris, DC, Zheng, G. The role of macrophages in kidney fibrosis. Front Physiol 2021;12:705838. https:\/\/doi.org\/10.3389\/fphys.2021.705838.","DOI":"10.3389\/fphys.2021.705838"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_041","doi-asserted-by":"crossref","unstructured":"Meng, XM. Inflammatory mediators and renal fibrosis. Adv Exp Med Biol 2019;1165:381\u2013406. https:\/\/doi.org\/10.1007\/978-981-13-8871-2_18.","DOI":"10.1007\/978-981-13-8871-2_18"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_042","doi-asserted-by":"crossref","unstructured":"Cruz-Solbes, AS, Youker, K. Epithelial to mesenchymal transition (EMT) and endothelial to mesenchymal transition (EndMT): role and implications in kidney fibrosis. Kidney Dev Dis 2017;60:345\u201372.","DOI":"10.1007\/978-3-319-51436-9_13"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_043","doi-asserted-by":"crossref","unstructured":"Tsuji, K, Nakanoh, H, Fukushima, K, Kitamura, S, Wada, J. MicroRNAs as biomarkers and therapeutic targets for acute kidney injury. Diagnostics 2023;13:2893. https:\/\/doi.org\/10.3390\/diagnostics13182893.","DOI":"10.3390\/diagnostics13182893"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_044","doi-asserted-by":"crossref","unstructured":"Liu, D, Zhang, X, Xu, J, Chen, C, Shao, H, Chen, X, et al.. Analysis of key microRNA molecules associated with acute kidney injury based on bioinformatics method. Medicine 2025;104:e41785. https:\/\/doi.org\/10.1097\/md.0000000000041785.","DOI":"10.1097\/MD.0000000000041785"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_045","doi-asserted-by":"crossref","unstructured":"Sch\u00f6nenberger, E, Martus, P, Bosserdt, M, Zimmermann, E, Tauber, R, Laule, M, et al.. Kidney injury after intravenous versus intra-arterial contrast agent in patients suspected of having coronary artery disease: a randomized trial. Radiology 2019;292:664\u201372.","DOI":"10.1148\/radiol.2019182220"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_046","doi-asserted-by":"crossref","unstructured":"Saleem, MS, Shah, N, Patel, P, Pancholy, S. TCT-335 contrast associated acute kidney injury following intra-arterial vs intravenous contrast administration: a meta-analysis. J\u00a0Am Coll Cardiol 2024;84:B83. https:\/\/doi.org\/10.1016\/j.jacc.2024.09.389.","DOI":"10.1016\/j.jacc.2024.09.389"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_047","doi-asserted-by":"crossref","unstructured":"McDonald, JS, Leake, CB, McDonald, RJ, Gulati, R, Katzberg, RW, Williamson, EE, et al.. Acute kidney injury after intravenous versus intra-arterial contrast material administration in a paired cohort. Investig Radiol 2016;51:804\u20139. https:\/\/doi.org\/10.1097\/rli.0000000000000298.","DOI":"10.1097\/RLI.0000000000000298"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_048","doi-asserted-by":"crossref","unstructured":"Moideen, A. P0584 a comparative study on the incidence of contrast induced nephropathy following intra-arterial versus intravenous contrast administration. Nephrol Dial Transplant 2020;35:gfaa142\u2013P0584. https:\/\/doi.org\/10.1093\/ndt\/gfaa142.p0584.","DOI":"10.1093\/ndt\/gfaa142.P0584"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_049","doi-asserted-by":"crossref","unstructured":"Guo, Y, Xu, X, Xue, Y, Zhao, C, Zhang, X, Cai, H. Mehran 2\u00a0contrast-associated acute kidney injury risk score: is it applicable to the Asian percutaneous coronary intervention population? Clinical and applied thrombosis\/hemostasis. 2022; 28:10760296221116353, https:\/\/doi.org\/10.1177\/10760296221116353.","DOI":"10.1177\/10760296221116353"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_050","doi-asserted-by":"crossref","unstructured":"Moitinho, MS, Barbosa, D, Galhardo, A, Caixeta, A, Santana-Santos, E, Cunha, M, et al.. Mehran vs. Mehran2 pre-procedure: which score better predicts risk of contrast-induced acute kidney injury in patients with acute coronary syndrome? PeerJ 2025;13:e19166. https:\/\/doi.org\/10.7717\/peerj.19166.","DOI":"10.7717\/peerj.19166"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_051","doi-asserted-by":"crossref","unstructured":"Sgura, FA, Bertelli, L, Monopoli, D, Leuzzi, C, Guerri, E, Spart\u00e0, I, et al.. Mehran contrast- induced nephropathy risk score predicts short-and long-term clinical outcomes in patients with ST-elevation\u2013myocardial infarction. Circ Cardiovasc Interv 2010;3:491\u20138. https:\/\/doi.org\/10.1161\/circinterventions.110.955310.","DOI":"10.1161\/CIRCINTERVENTIONS.110.955310"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_052","doi-asserted-by":"crossref","unstructured":"Wu, T, Li, R, Chen, J, Tian, X, Zhang, R, Hou, X. Age, creatinine, and ejection fraction score is a risk factor for acute kidney injury after surgical aortic valve replacement. Ren Fail 2025;47:2444401. https:\/\/doi.org\/10.1080\/0886022x.2024.2444401.","DOI":"10.1080\/0886022X.2024.2444401"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_053","doi-asserted-by":"crossref","unstructured":"Demirci, G, Demir, AR, Kahraman, S, \u00c7amc\u0131, S, Y\u0131lmaz, E. Predictive value of ACEF score for acute kidney injury after surgical aortic valve replacement. Eur Res J 2024;10:254\u201361. https:\/\/doi.org\/10.18621\/eurj.1334048.","DOI":"10.18621\/eurj.1334048"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_054","doi-asserted-by":"crossref","unstructured":"Uygur, B, Celik, O, Demir, AR, Sahin, AA, Guner, A, Avci, Y, et al.. A simplified acute kidney injury predictor following transcatheter aortic valve implantation: ACEF score. Pol Heart J 2021;79:662\u20138. https:\/\/doi.org\/10.33963\/KP.15933.","DOI":"10.33963\/KP.15933"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_055","doi-asserted-by":"crossref","unstructured":"Avci, Y, Demir, AR, G\u00fcler, A, Aktemur, T, Bulut, U, Demirci, G, et al.. A simplified acute kidney injury predictor following endovascular aortic repair: ACEF score. Vascular 2023;31:26\u201332. https:\/\/doi.org\/10.1177\/17085381211059403.","DOI":"10.1177\/17085381211059403"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_056","doi-asserted-by":"crossref","unstructured":"Demirci, G, Demir, AR, Kahraman, S, \u00c7amc\u0131, S, Y\u0131lmaz, E. Predictive value of ACEF score for acute kidney injury after surgical aortic valve replacement. Eur Res J 2024;10:254\u201361. https:\/\/doi.org\/10.18621\/eurj.1334048.","DOI":"10.18621\/eurj.1334048"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_057","doi-asserted-by":"crossref","unstructured":"Wu, T, Li, R, Chen, J, Tian, X, Zhang, R, Hou, X. Age, creatinine, and ejection fraction score is a risk factor for acute kidney injury after surgical aortic valve replacement. Ren Fail 2025;47:2444401. https:\/\/doi.org\/10.1080\/0886022x.2024.2444401.","DOI":"10.1080\/0886022X.2024.2444401"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_058","unstructured":"Larson, TS, Hudson, K, Mertz, JI, Romero, JC, Knox, FG. Renal vasoconstrictive response to contrast medium: the role of sodium balance and the renin-angiotensin system. J\u00a0Lab Clin Med 1983;101:385\u201391."},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_059","doi-asserted-by":"crossref","unstructured":"Nygren, A, Ulfendahl, HR, Fasching, A. Effects of high-and low-osmolar contrast media on renal plasma flow and glomerular filtration rate in euvolaemic and dehydrated rats: a comparison between ioxithalamate, iopamidol, iohexol and ioxaglate. Acta Radiol 1989;30:383\u20139. https:\/\/doi.org\/10.3109\/02841858909174703.","DOI":"10.3109\/02841858909174703"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_060","doi-asserted-by":"crossref","unstructured":"Katzberg, RW, Morris, TW, Schulman, G, Caldicott, WJ, Boylan, LM, Foley, MJ, et al.. Reactions to intravenous contrast media. Part II: acute renal response in euvolemic and dehydrated dogs. Radiology 1983;147:331\u20134. https:\/\/doi.org\/10.1148\/radiology.147.2.6836113.","DOI":"10.1148\/radiology.147.2.6836113"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_061","doi-asserted-by":"crossref","unstructured":"Porter, GA. Effects of contrast agents on renal function. Investig Radiol 1993;28:1\u20135. https:\/\/doi.org\/10.1097\/00004424-199311001-00001.","DOI":"10.1097\/00004424-199311001-00001"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_062","doi-asserted-by":"crossref","unstructured":"Pattharanitima, P, Tasanarong, A. Pharmacological strategies to prevent contrast-induced acute kidney injury. BioMed Res Int 2014;2014:236930. https:\/\/doi.org\/10.1155\/2014\/236930.","DOI":"10.1155\/2014\/236930"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_063","unstructured":"Turkistani, YA, Alshami, TM, Almatrafi, SJ, Alahmadi, AO, Al Edrisy, SA, Bazuhair, GY, et al.. Evaluation of contrast-induced acute kidney injury (CI-AKI). Int J Pharmaceut Res Allied Sci 2020;9:99\u2013104."},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_064","doi-asserted-by":"crossref","unstructured":"Weisbord, SD, Palevsky, PM. Prevention of contrast-induced nephropathy with volume expansion. Clin J Am Soc Nephrol 2008;3:273\u201380. https:\/\/doi.org\/10.2215\/cjn.02580607.","DOI":"10.2215\/CJN.02580607"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_065","doi-asserted-by":"crossref","unstructured":"Seeliger, E, Sendeski, M, Rihal, CS, Persson, PB. Contrast-induced kidney injury: mechanisms, risk factors, and prevention. Eur Heart J 2012;33:2007\u201315. https:\/\/doi.org\/10.1093\/eurheartj\/ehr494.","DOI":"10.1093\/eurheartj\/ehr494"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_066","doi-asserted-by":"crossref","unstructured":"Maeder, M, Klein, M, Fehr, T, Rickli, H. Contrast nephropathy: review focusing on prevention. J\u00a0Am Coll Cardiol 2004;44:1763\u201371. https:\/\/doi.org\/10.1016\/j.jacc.2004.06.075.","DOI":"10.1016\/j.jacc.2004.06.075"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_067","doi-asserted-by":"crossref","unstructured":"Han, XF, Zhang, XX, Liu, KM, Tan, H, Zhang, Q. Contrast-induced nephropathy in patients with diabetes mellitus between iso-and low-osmolar contrast media: a meta-analysis of full-text prospective, randomized controlled trials. PLoS One 2018;13:e0194330. https:\/\/doi.org\/10.1371\/journal.pone.0194330.","DOI":"10.1371\/journal.pone.0194330"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_068","doi-asserted-by":"crossref","unstructured":"Aspelin, P, Aubry, P, Fransson, SG, Strasser, R, Willenbrock, R, Berg, KJ. Nephrotoxic effects in high-risk patients undergoing angiography. N\u00a0Engl J Med 2003;348:491\u20139. https:\/\/doi.org\/10.1056\/nejmoa021833.","DOI":"10.1056\/NEJMoa021833"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_069","doi-asserted-by":"crossref","unstructured":"Kuhn, MJ, Chen, N, Sahani, DV, Reimer, D, Van Beek, EJ, Heiken, JP, et al.. The PREDICT study: a randomized double-blind comparison of contrast-induced nephropathy after low-or isoosmolar contrast agent exposure. Am J Roentgenol 2008;191:151\u20137. https:\/\/doi.org\/10.2214\/ajr.07.3370.","DOI":"10.2214\/AJR.07.3370"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_070","doi-asserted-by":"crossref","unstructured":"Solomon, R. The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high-risk patients. Kidney Int 2005;68:2256\u201363. https:\/\/doi.org\/10.1111\/j.1523-1755.2005.00684.x.","DOI":"10.1111\/j.1523-1755.2005.00684.x"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_071","doi-asserted-by":"crossref","unstructured":"Aoun, J, Nicolas, D, Brown, JR, Jaber, BL. Maximum allowable contrast dose and prevention of acute kidney injury following cardiovascular procedures. Curr Opin Nephrol Hypertens 2018;27:121\u20139. https:\/\/doi.org\/10.1097\/mnh.0000000000000389.","DOI":"10.1097\/MNH.0000000000000389"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_072","doi-asserted-by":"crossref","unstructured":"Brown, JR, Robb, JF, Block, CA, Schoolwerth, AC, Kaplan, AV, O\u2019Connor, GT, et al.. Does safe dosing of iodinated contrast prevent contrast-induced acute kidney injury? Circ Cardiovasc Interv 2010;3:346\u201350. https:\/\/doi.org\/10.1161\/circinterventions.109.910638.","DOI":"10.1161\/CIRCINTERVENTIONS.109.910638"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_073","doi-asserted-by":"crossref","unstructured":"Hattar, L, Assaker, JP, Aoun, J, Price, LL, Carrozza, J, Jaber, BL. Revising the maximal contrast dose for predicting acute kidney injury following coronary intervention. Am J Nephrol 2021;52:328\u201335. https:\/\/doi.org\/10.1159\/000515382.","DOI":"10.1159\/000515382"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_074","doi-asserted-by":"crossref","unstructured":"Aoun, J, Hattar, L, Jaber, B. Refining the maximal allowable contrast dose in percutaneous coronary interventions. JACC 2020;75:1340. https:\/\/doi.org\/10.1016\/s0735-1097(20)31967-7.","DOI":"10.1016\/S0735-1097(20)31967-7"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_075","doi-asserted-by":"crossref","unstructured":"Zhou, X, Dai, J, Xu, X, Wang, Z, Xu, H, Chen, J, et al.. Comparative efficacy of statins for prevention of contrast-induced acute kidney injury in patients with chronic kidney disease: a network meta-analysis. Angiology 2019;70:305\u201316. https:\/\/doi.org\/10.1177\/0003319718801246.","DOI":"10.1177\/0003319718801246"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_076","doi-asserted-by":"crossref","unstructured":"Ball, T, McCullough, PA. Statins for the prevention of contrast-induced acute kidney injury. Nephron Clin Pract 2014;127:165\u201371. https:\/\/doi.org\/10.1159\/000363202.","DOI":"10.1159\/000363202"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_077","doi-asserted-by":"crossref","unstructured":"Ukaigwe, A, Karmacharya, P, Mahmood, M, Pathak, R, Aryal, MR, Jalota, L, et al.. Meta- analysis on efficacy of statins for prevention of contrast-induced acute kidney injury in patients undergoing coronary angiography. Am J Cardiol 2014;114:1295\u2013302. https:\/\/doi.org\/10.1016\/j.amjcard.2014.07.059.","DOI":"10.1016\/j.amjcard.2014.07.059"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_078","doi-asserted-by":"crossref","unstructured":"Lee, JM, Park, J, Jeon, KH, Jung, JH, Lee, SE, Han, JK, et al.. Efficacy of short-term high-dose statin pretreatment in prevention of contrast-induced acute kidney injury: updated study- level meta-analysis of 13 randomized controlled trials. PLoS One 2014;9:e111397. https:\/\/doi.org\/10.1371\/journal.pone.0111397.","DOI":"10.1371\/journal.pone.0111397"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_079","doi-asserted-by":"crossref","unstructured":"S\u016fva, M, Kala, P, Poloczek, M, Ka\u0148ovsk\u00fd, J, \u0160t\u00edpal, R, Radvan, M, et al.. Contrast-induced acute kidney injury and its contemporary prevention. Front Cardiovasc Med 2022;9:1073072. https:\/\/doi.org\/10.3389\/fcvm.2022.1073072.","DOI":"10.3389\/fcvm.2022.1073072"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_080","doi-asserted-by":"crossref","unstructured":"Xu, R, Tao, A, Bai, Y, Deng, Y, Chen, G. Effectiveness of N\u2010acetylcysteine for the prevention of contrast\u2010induced nephropathy: a systematic review and meta\u2010analysis of randomized controlled trials. J\u00a0Am Heart Assoc 2016;5:e003968. https:\/\/doi.org\/10.1161\/jaha.116.003968.","DOI":"10.1161\/JAHA.116.003968"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_081","doi-asserted-by":"crossref","unstructured":"de Laforcade, L, Bobot, M, Bellin, MF, Clement, O, Grange, S, Grenier, N, et al.. Kidney and contrast media: common viewpoint of the French nephrology societies (SFNDT, FIRN, CJN) and the French Radiological Society (SFR) following ESUR guidelines. Diagn Interv Imaging 2021;102:131\u20139. https:\/\/doi.org\/10.1016\/j.diii.2021.01.007.","DOI":"10.1016\/j.diii.2021.01.007"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_082","doi-asserted-by":"crossref","unstructured":"Hafiz, AM, Jan, MF, Mori, N, Shaikh, F, Wallach, J, Bajwa, T, et al.. Prevention of contrast\u2010 induced acute kidney injury in patients with stable chronic renal disease undergoing elective percutaneous coronary and peripheral interventions: randomized comparison of two preventive strategies. Cathet Cardiovasc Interv 2012;79:929\u201337. https:\/\/doi.org\/10.1002\/ccd.23148.","DOI":"10.1002\/ccd.23148"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_083","doi-asserted-by":"crossref","unstructured":"Gonzales, DA, Norsworthy, KJ, Kern, SJ, Banks, S, Sieving, PC, Star, RA, et al.. A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity. BMC Med 2007;5:18. https:\/\/doi.org\/10.1186\/1741-7015-5-32.","DOI":"10.1186\/1741-7015-5-32"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_084","doi-asserted-by":"crossref","unstructured":"Wang, N, Qian, P, Kumar, S, Yan, TD, Phan, K. The effect of N-acetylcysteine on the incidence of contrast-induced kidney injury: a systematic review and trial sequential analysis. Int J Cardiol 2016;209:319\u201327. https:\/\/doi.org\/10.1016\/j.ijcard.2016.02.083.","DOI":"10.1016\/j.ijcard.2016.02.083"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_085","unstructured":"Alessandri, N, Lanzi, L, Garante, CM, Tersigni, F, Sergiacomi, R, Petrassi, M, et al.. Prevention of acute renal failure post-contrast imaging in cardiology: a randomized study. Eur Rev Med Pharmacol Sci 2013;17:13\u201321."},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_086","doi-asserted-by":"crossref","unstructured":"Ali-Hassan-Sayegh, S, Mirhosseini, SJ, Ghodratipour, Z, Sarrafan-Chaharsoughi, Z, Rahimizadeh, E, Karimi-Bondarabadi, AA, et al.. Strategies preventing contrast-induced nephropathy after coronary angiography: a comprehensive meta-analysis and systematic review of 125 randomized controlled trials. Angiology 2017;68:389\u2013413. https:\/\/doi.org\/10.1177\/0003319716661445.","DOI":"10.1177\/0003319716661445"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_087","doi-asserted-by":"crossref","unstructured":"Hosseini, ZS, Jamili, MJ, Ensan, B, Donyadideh, G, Shahri, B, Eshraghi, H, et al.. Short-term effects of empagliflozin on preventing contrast induced acute kidney injury in patients undergoing percutaneous coronary intervention, a randomised trial. Sci Rep 2025;15:3940. https:\/\/doi.org\/10.1038\/s41598-024-82991-7.","DOI":"10.1038\/s41598-024-82991-7"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_088","doi-asserted-by":"crossref","unstructured":"Santos-Gallego, CG, Palamara, G, Requena-Ibanez, JA, Vargas, AP, Mohebi, R, Abascal, V, et al.. Pretreatment with SGLT2 inhibitors ameliorates contrast-induced nephropathy. J\u00a0Am Coll Cardiol 2020;75:1405. https:\/\/doi.org\/10.1016\/s0735-1097(20)32032-5.","DOI":"10.1016\/S0735-1097(20)32032-5"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_089","doi-asserted-by":"crossref","unstructured":"Hua, R, Ding, N, Guo, H, Wu, Y, Yuan, Z, Li, T. Contrast-induced acute kidney injury in patients on SGLT2 inhibitors undergoing percutaneous coronary interventions: a propensity-matched analysis. Front Cardiovasc Med 2022;9:918167. https:\/\/doi.org\/10.3389\/fcvm.2022.918167.","DOI":"10.3389\/fcvm.2022.918167"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_090","doi-asserted-by":"crossref","unstructured":"Paolisso, P, Bergamaschi, L, Cesaro, A, Gallinoro, E, Gragnano, F, Sardu, C, et al.. Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: insight from SGLT2-I AMI PROTECT registry. Diabetes Res Clin Pract 2023;202:110766. https:\/\/doi.org\/10.1016\/j.diabres.2023.110766.","DOI":"10.1016\/j.diabres.2023.110766"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_091","doi-asserted-by":"crossref","unstructured":"Nardi, G, Marchi, E, Allinovi, M, Lugli, G, Biagiotti, L, Di Muro, FM, et al.. Contrast-induced acute kidney injury in patients with heart failure on sodium\u2013glucose cotransporter-2 inhibitors undergoing radiocontrast agent invasive procedures: a propensity-matched analysis. J\u00a0Clin Med 2024;13:2041. https:\/\/doi.org\/10.3390\/jcm13072041.","DOI":"10.3390\/jcm13072041"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_092","doi-asserted-by":"crossref","unstructured":"Idowu, AB, Adebolu, O, Lo, KB, Roy, MO, Soman, SS, Janani, R. C-58| Kidney outcomes with sodium-glucose Co-transporter-2 inhibitors use in patients undergoing revascularization for acute coronary syndromes: a propensity-matched analysis. J\u00a0Soc Cardiovasc Angiography Interv 2024;3:101686. https:\/\/doi.org\/10.1016\/j.jscai.2024.101686.","DOI":"10.1016\/j.jscai.2024.101686"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_093","doi-asserted-by":"crossref","unstructured":"Sharp, AJ, Patel, N, Reeves, BC, Angelini, GD, Fiorentino, F. Pharmacological interventions for the prevention of contrast-induced acute kidney injury in high-risk adult patients undergoing coronary angiography: a systematic review and meta-analysis of randomised controlled trials. Open Heart 2019;6:e000864. https:\/\/doi.org\/10.1136\/openhrt-2018-000864.","DOI":"10.1136\/openhrt-2018-000864"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_094","doi-asserted-by":"crossref","unstructured":"Lukwaro, A, Lu, Y, Chen, J, Tang, Y. Trimetazidine as an adjunct to standard hydration reduces the incidence of contrast-induced acute kidney injury in patients with renal insufficiency undergoing coronary angiography or percutaneous cardiac intervention: a systematic review and meta-analysis. BMC Nephrol 2024;25:471. https:\/\/doi.org\/10.1186\/s12882-024-03872-9.","DOI":"10.1186\/s12882-024-03872-9"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_095","doi-asserted-by":"crossref","unstructured":"Su, X, Xie, X, Liu, L, Lv, J, Song, F, Perkovic, V, et al.. Comparative effectiveness of 12 treatment strategies for preventing contrast-induced acute kidney injury: a systematic review and Bayesian network meta-analysis. Am J Kidney Dis 2017;69:69\u201377. https:\/\/doi.org\/10.1053\/j.ajkd.2016.07.033.","DOI":"10.1053\/j.ajkd.2016.07.033"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_096","doi-asserted-by":"crossref","unstructured":"Quintavalle, C, Donnarumma, E, Fiore, D, Briguori, C, Condorelli, G. Therapeutic strategies to prevent contrast-induced acute kidney injury. Curr Opin Cardiol 2013;28:676\u201382. https:\/\/doi.org\/10.1097\/hco.0b013e3283653f41.","DOI":"10.1097\/HCO.0b013e3283653f41"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_097","doi-asserted-by":"crossref","unstructured":"Gong, X, Wang, Q, Tang, X, Wang, Y, Fu, D, Lu, H, et al.. Tetramethylpyrazine prevents contrast-induced nephropathy by inhibiting p38 MAPK and FoxO1 signaling pathways. Am J Nephrol 2013;37:199\u2013207. https:\/\/doi.org\/10.1159\/000347033.","DOI":"10.1159\/000347033"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_098","doi-asserted-by":"crossref","unstructured":"Li, J, Gong, X. Tetramethylpyrazine: an active ingredient of Chinese herbal medicine with therapeutic potential in acute kidney injury and renal fibrosis. Front Pharmacol 2022;13:820071. https:\/\/doi.org\/10.3389\/fphar.2022.820071.","DOI":"10.3389\/fphar.2022.820071"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_099","doi-asserted-by":"crossref","unstructured":"Zhu, Z, Li, J, Song, Z, Li, T, Li, Z, Gong, X. Tetramethylpyrazine attenuates renal tubular epithelial cell ferroptosis in contrast-induced nephropathy by inhibiting transferrin receptor and intracellular reactive oxygen species. Clin Sci 2024;138:235\u201349. https:\/\/doi.org\/10.1042\/cs20231184.","DOI":"10.1042\/CS20231184"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_100","doi-asserted-by":"crossref","unstructured":"Huang, X, Guo, X, Yan, G, Zhang, Y, Yao, Y, Qiao, Y, et al.. Dapagliflozin attenuates contrast- induced acute kidney injury by regulating the HIF-1\u03b1\/HE4\/NF-\u03baB pathway. J\u00a0Cardiovasc Pharmacol 2022;79:904\u201313. https:\/\/doi.org\/10.1097\/fjc.0000000000001268.","DOI":"10.1097\/FJC.0000000000001268"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_101","doi-asserted-by":"crossref","unstructured":"Chang, YK, Choi, H, Jeong, JY, Na, KR, Lee, KW, Lim, BJ, et al.. Dapagliflozin, SGLT2 inhibitor, attenuates renal ischemia-reperfusion injury. PLoS One 2016;11:e0158810. https:\/\/doi.org\/10.1371\/journal.pone.0158810.","DOI":"10.1371\/journal.pone.0158810"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_102","doi-asserted-by":"crossref","unstructured":"Jallawee, HQ, Janabi, AM. Potential nephroprotective effect of dapagliflozin against renal ischemia reperfusion injury in rats via activation of autophagy pathway and inhibition of inflammation, oxidative stress and apoptosis. South East Eur J Public Health 2024;24:488\u2013500. https:\/\/doi.org\/10.70135\/seejph.vi.1009.","DOI":"10.70135\/seejph.vi.1009"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_103","doi-asserted-by":"crossref","unstructured":"Li, X, Yao, L, Zeng, X, Hu, B, Zhang, X, Wang, J, et al.. miR-30c-5p alleviated pyroptosis during sepsis-induced acute kidney injury via targeting TXNIP. Inflammation 2021;44:217\u201328. https:\/\/doi.org\/10.1007\/s10753-020-01323-9.","DOI":"10.1007\/s10753-020-01323-9"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_104","doi-asserted-by":"crossref","unstructured":"Gan, XG, Wang, ZH, Xu, HT. Mechanism of miRNA-141-3p in calcium oxalate-induced renal tubular epithelial cell injury via NLRP3-mediated pyroptosis. Kidney Blood Press Res 2022;47:300\u20138. https:\/\/doi.org\/10.1159\/000521795.","DOI":"10.1159\/000521795"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_105","doi-asserted-by":"crossref","unstructured":"Wei, W, Yao, YY, Bi, HY, Zhai, Z, Gao, Y. miR-21 protects against lipopolysaccharide- stimulated acute kidney injury and apoptosis by targeting CDK6. Ann Transl Med 2020;8:303. https:\/\/doi.org\/10.21037\/atm.2020.03.01.","DOI":"10.21037\/atm.2020.03.01"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_106","doi-asserted-by":"crossref","unstructured":"Zankar, S, Trentin-Sonoda, M, Vi\u00f1as, JL, Rodriguez, RA, Bailey, A, Allan, D, et al.. Therapeutic effects of micro-RNAs in preclinical studies of acute kidney injury: a systematic review and meta-analysis. Sci Rep 2021;11:9100. https:\/\/doi.org\/10.1038\/s41598-021-88746-y.","DOI":"10.1038\/s41598-021-88746-y"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_107","doi-asserted-by":"crossref","unstructured":"Martin-Sanchez, D, Fontecha-Barriuso, M, Martinez-Moreno, JM, Ramos, AM, Sanchez-Ni\u00f1o, MD, Guerrero-Hue, M, et al.. Ferroptosis and kidney disease. Nefrologia 2020;40:384\u201394. https:\/\/doi.org\/10.1016\/j.nefroe.2020.09.006.","DOI":"10.1016\/j.nefro.2020.03.005"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_108","doi-asserted-by":"crossref","unstructured":"Lyu, G, Liao, H, Li, R. Ferroptosis and renal fibrosis: mechanistic insights and emerging therapeutic targets. Ren Fail 2025;47:2498629. https:\/\/doi.org\/10.1080\/0886022x.2025.2498629.","DOI":"10.1080\/0886022X.2025.2498629"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_109","doi-asserted-by":"crossref","unstructured":"Huang, X, Song, Y, Wei, L, Guo, J, Xu, W, Li, M. The emerging roles of ferroptosis in organ fibrosis and its potential therapeutic effect. Int Immunopharmacol 2023;116:109812. https:\/\/doi.org\/10.1016\/j.intimp.2023.109812.","DOI":"10.1016\/j.intimp.2023.109812"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_110","doi-asserted-by":"crossref","unstructured":"Lewis, HD, Liddle, J, Coote, JE, Atkinson, SJ, Barker, MD, Bax, BD, et al.. Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation. Nat Chem Biol 2015;11:189\u201391. https:\/\/doi.org\/10.1038\/nchembio.1735.","DOI":"10.1038\/nchembio.1735"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_111","doi-asserted-by":"crossref","unstructured":"Knight, JS, Subramanian, V, O\u2019Dell, AA, Yalavarthi, S, Zhao, W, Smith, CK, et al.. Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL\/lpr mice. Ann Rheum Dis 2015;74:2199\u2013206. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205365.","DOI":"10.1136\/annrheumdis-2014-205365"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_112","doi-asserted-by":"crossref","unstructured":"Bolisetty, S, Zarjou, A, Agarwal, A. Heme oxygenase 1 as a therapeutic target in acute kidney injury. Am J Kidney Dis 2017;69:531\u201345. https:\/\/doi.org\/10.1053\/j.ajkd.2016.10.037.","DOI":"10.1053\/j.ajkd.2016.10.037"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_113","doi-asserted-by":"crossref","unstructured":"Nath, KA. Heme oxygenase-1 and acute kidney injury. Curr Opin Nephrol Hypertens 2014;23:17\u201324. https:\/\/doi.org\/10.1097\/01.mnh.0000437613.88158.d3.","DOI":"10.1097\/01.mnh.0000437613.88158.d3"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_114","doi-asserted-by":"crossref","unstructured":"Ferrandiz, ML, Devesa, I. Inducers of heme oxygenase-1. Curr Pharm Des 2008;14:473\u201386. https:\/\/doi.org\/10.2174\/138161208783597399.","DOI":"10.2174\/138161208783597399"},{"key":"2026060111012258383_j_jbcpp-2025-0222_ref_115","doi-asserted-by":"crossref","unstructured":"McCullough, PA, Choi, JP, Feghali, GA, Schussler, JM, Stoler, RM, Vallabahn, RC, et al.. Contrast-induced acute kidney injury. J\u00a0Am Coll Cardiol 2016;68:1465\u201373. https:\/\/doi.org\/10.1016\/j.jacc.2016.05.099.","DOI":"10.1016\/j.jacc.2016.05.099"}],"container-title":["Journal of Basic and Clinical Physiology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2025-0222\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2025-0222\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T11:04:31Z","timestamp":1780311871000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2025-0222\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":115,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,5,11]]},"published-print":{"date-parts":[[2026,6,1]]}},"alternative-id":["10.1515\/jbcpp-2025-0222"],"URL":"https:\/\/doi.org\/10.1515\/jbcpp-2025-0222","relation":{},"ISSN":["0792-6855","2191-0286"],"issn-type":[{"value":"0792-6855","type":"print"},{"value":"2191-0286","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]}}}